According to a new research report “Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff Akt/PKB inhibitors therapeutics currently exhibits a proliferating pipeline with 23 therapeutic candidates.


Download the sample report @ https://www.pharmaproff.com/request-sample/1154

Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells. Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.

Get the detailed analysis @ https://www.pharmaproff.com/report/pkb-inhibitors-pipeline-analysis

The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd. announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.

Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.

Bone metastases is a common form of cancer of the skeleton that inhabits in bone marrow and stimulates the local bone activity.


In this condition, the normal bone homeostasis disrupts which leads to the development of the tumour. Some of the major symptoms observed in patients with bone metastases are bone pain, spinal cord compression, and high blood calcium levels.

Bone metastases can be diagnosed by various types of imaging tests such as X-Ray, bone scan, positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) scan, blood tests, urine tests, and bone biopsy. ChemoCentryx, Inc. is in the process of developing CCX354 as a CCR1 receptor antagonist for the treatment of bone metastases. Moreover, Amgen Inc. is developing denosumab as a RANKL ligand inhibitor for the treatment of this medical condition. Pfizer Inc., and Eli Lilly and Company are also key players having drugs for bone metastases in their pipeline.

For more information about Bone Metastases Therapeutics Pipeline Get the sample report at:
https://www.pharmaproff.com/request-sample/1112